|
1.
|
|
13 p, 7.4 MB |
Zn(II) and Cd(II) complexes with 3-furoic acid. Exploring the role of C-H···O interactions
/
Sanchez Ferez, Francisco (Universitat Autònoma de Barcelona. Departament de Química) ;
Ejarque, Daniel (Universitat Autònoma de Barcelona. Departament de Química) ;
Calvet, Teresa (Universitat de Barcelona. Departament de Mineralogia, Petrologia i Geologia Aplicada) ;
Font-Bardia, Mercè (Universitat de Barcelona. Unitat de Difracció de Raig-X) ;
Pons Picart, Josefina (Universitat Autònoma de Barcelona. Departament de Química)
Hydrogen bond interactions implying Csingle bondH groups and O atoms either from carboxylate, carbonyl, or ether functionalities have been demonstrated to play a pivotal role in the packing of crystal structures. [...]
2024 -  10.1016/j.molstruc.2024.138206
Journal of molecular structure, Vol. 1309 (August 2024) , art. 138206
|
|
|
2.
|
|
38 p, 2.1 MB |
Developing Photo-Activable Ruthenium (II) Complexes for PDT : Synthesis, Characterization, Photophysical and Biological Studies
/
Parella, Clara (Universitat de Girona) ;
Blanquer Jerez, Andreu (Universitat Autònoma de Barcelona. Departament de Biologia Cel·lular, de Fisiologia i d'Immunologia) ;
Sinha, Sohini (Institut de Ciència de Materials de Barcelona) ;
Hümpfner, Evelyn (Budapest University of Technology and Economics) ;
Hernando Cubero, Jordi (Universitat Autònoma de Barcelona. Departament de Química) ;
Mora, Eloi (Universitat de Girona) ;
Fontrodona, Xavier (Universitat de Girona) ;
Kelemen, Zsolt (Budapest University of Technology and Economics) ;
Nogués, C. (Carme) (Universitat Autònoma de Barcelona. Departament de Biologia Cel·lular, de Fisiologia i d'Immunologia) ;
Núñez, Rosario (Institut de Ciència de Materials de Barcelona) ;
Romero, Isabel (Universitat de Girona)
The easy tunable photophysical properties of Ru(II) polypyridyl complexes, together with their water solubility, photochemical stability and high biocompatibility make them suitable as agents for photodynamic therapy (PDT). [...]
2024 - 10.1016/j.dyepig.2024.111985
Dyes and pigments, Vol. 224 (may 2024)
|
|
|
3.
|
|
23 p, 1.3 MB |
European guideline (EuroGuiDerm) on atopic eczema - part II : non-systemic treatments and treatment recommendations for special AE patient populations
/
Wollenberg, Andreas (Brussels University Hospital) ;
Kinberger, Maria (Charité - Berlin University Medicine) ;
Arents, B. (European Federation of Allergy and Airways Diseases Patients' Associations) ;
Aszodi, N. (LMU Munich) ;
Avila Valle, G. (Charité - Berlin University Medicine) ;
Barbarot, Sebastien (Nantes University) ;
Bieber, T. (University Hospital of Bonn) ;
Brough, H.A. (King's College London) ;
Calzavara Pinton, P. (University of Brescia) ;
Christen-Zäch, S. (Lausanne University Hospital) ;
Deleuran, M. (Aarhus University Hospital (Aarhus, Dinamarca)) ;
Dittmann, M. (Charité - Berlin University Medicine) ;
Dressler, C. (Charité - Berlin University Medicine) ;
Fink-Wagner, A.H. (Global Allergy and Airways diseases Patient Platform) ;
Fosse, N. (University Hospital Basel) ;
Gáspár, K. (University of Debrecen) ;
Gerbens, L. (Amsterdam UMC) ;
Gieler, U. (University of Giessen) ;
Girolomoni, Giampiero (University of Verona) ;
Gregoriou, S. (National and Kapodistrian University of Athens) ;
Mortz, C. G. (University of Southern Denmark) ;
Nast, A. (Charité - Berlin University Medicine) ;
Nygaard, U. (Aarhus University Hospital (Aarhus, Dinamarca)) ;
Redding, M. (Eczema Outreach Support) ;
Rehbinder, E.M. (Oslo University Hospital (Oslo, Noruega)) ;
Ring, J. (Technical University Munich) ;
Rossi, M. (Spedali Civili Hospital Brescia) ;
Serra-Baldrich, E (Institut d'Investigació Biomèdica Sant Pau) ;
Simon, D. (University of Bern) ;
Szalai, Z.Z. (Heim Pál National Children's Institute Budapest) ;
Szepietowski, J.C. (Wrocław Medical University) ;
Torrelo, A. (Hospital Infantil Niño Jesús) ;
Werfel, T. (Hannover Medical School) ;
Flohr, C. (Guy's & St Thomas' NHS Foundation Trust) ;
Universitat Autònoma de Barcelona
The evidence- and consensus-based guideline on atopic eczema was developed in accordance with the EuroGuiDerm Guideline and Consensus Statement Development Manual. Four consensus conferences were held between December 2020 and July 2021. [...]
2022 - 10.1111/jdv.18429
Journal of the European Academy of Dermatology and Venereology, Vol. 36 Núm. 11 (november 2022) , p. 1904-1926
|
|
|
4.
|
|
|
5.
|
|
9 p, 603.3 KB |
Teclistamab Improves Patient-Reported Symptoms and Health-Related Quality of Life in Relapsed or Refractory Multiple Myeloma : Results From the Phase II MajesTEC-1 Study
/
Martin, Thomas G. (University of California San Francisco, USA) ;
Moreau, Philippe (University Hospital Hôtel-Dieu, Nantes, France) ;
Usmani, Saad Z. (Levine Cancer Institute/Atrium Health, Charlotte, NC) ;
Garfall, Alfred (University of Pennsylvania, Philadelphia, PA) ;
Mateos, M. V (Hospital Universitario de Salamanca) ;
San-Miguel, Jesús F. (Clínica Universidad de Navarra) ;
Oriol, Albert (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Nooka, Ajay K. (Emory University, Atlanta, GA) ;
Rosiñol, Laura (Hospital Clínic i Provincial de Barcelona) ;
Chari, Ajay (Mount Sinai School of Medicine, New York, USA) ;
Karlin, Lionel (Centre Hospitalier Lyon Sud, Pierre-Bénite, France) ;
Krishnan, Amrita (City of Hope National Medical Center (Duarte, Estats Units d'Amèrica)) ;
Bahlis, Nizar (University of Calgary, Canada) ;
Popat, Rakesh (University College London) ;
Besemer, Britta (University of Tuebingen, Tuebingen, Germany) ;
Martínez-López, Joaquín (Hospital Universitario 12 de Octubre (Madrid)) ;
Delforge, Michel (Universitaire Ziekenhuizen Leuven, Belgium) ;
Trancucci, Danielle (Janssen Research & Development, Raritan, NJ) ;
Pei, Lixia (Janssen Research & Development, Raritan, NJ) ;
Kobos, Rachel (Janssen Research & Development, Raritan, NJ) ;
Fastenau, John (Janssen Research & Development, Raritan, NJ) ;
Gries, Katharine S. (Janssen Research & Development, Raritan, NJ) ;
van de Donk, Niels W.C.J. (Amsterdam University Medical Center, Vrije Universiteit Amsterdam, The Netherlands)
Introduction: Patients with relapsed or refractory multiple myeloma (RRMM) report significantly lower HRQoL compared with patients with newly diagnosed MM and experience further deterioration in HRQoL with each relapse and subsequent treatment. [...]
2023 - 10.1016/j.clml.2023.11.001
Clinical Lymphoma, Myeloma & Leukemia, 2023
|
|
|
6.
|
|
|
7.
|
|
7 p, 784.4 KB |
Phase II Study of Yttrium-90-Ibritumomab Tiuxetan as Part of Reduced-Intensity Conditioning (with Melphalan, Fludarabine ± Thiotepa) for Allogeneic Transplantation in Relapsed or Refractory Aggressive B Cell Lymphoma : A GELTAMO Trial
/
Cabrero, Monica (Hospital Universitario Salamanca i IBSAL (Instituto Biosanitario de Salamanca)) ;
Martín García-Sancho, Alejandro (Hospital Universitario Salamanca i IBSAL (Instituto Biosanitario de Salamanca)) ;
Briones Meijide, Javier (Institut d'Investigació Biomèdica Sant Pau) ;
Gayoso, Jorge (Hospital General Universitario Gregorio Marañón) ;
Jarque, Isidro (Hospital Universitari i Politècnic La Fe (València)) ;
López, Javier (Hospital Universitario Ramón y Cajal (Madrid)) ;
Grande García, Carlos (Hospital 12 de Octubre (Madrid)) ;
Heras, Inmaculada (Hospital Morales Messeguer) ;
Arranz, Reyes (Hospital Universitario de la Princesa (Madrid)) ;
Bernal, Teresa (Hospital Universitario Central de Asturias) ;
Perez-Lopez, Estefenia (Hospital Universitario Salamanca i IBSAL (Instituto Biosanitario de Salamanca)) ;
López-Godino, Oriana (Hospital Morales Messeguer) ;
Conde, Eulogio (Hospital Universitario Marqués de Valdecilla (Santander, Cantabria)) ;
Caballero, Dolores (Hospital Universitario Salamanca i IBSAL (Instituto Biosanitario de Salamanca)) ;
Universitat Autònoma de Barcelona
We designed a phase II clinical trial including Y-90 ibritumomab-tiuxetan as part of a reduced-intensity conditioning (RIC) allogeneic stem cell transplantation (AlloSCT) in high-risk non-Hodgkin lymphoma (Clinical Trials Identifier: NCT00644371). [...]
2017 - 10.1016/j.bbmt.2016.10.003
Biology of blood and marrow transplantation, Vol. 23 Núm. 1 (january 2017) , p. 53-59
|
|
|
8.
|
|
20 p, 493.6 KB |
Diálogo interdisciplinar : aproximación biosocial a la parentalidad. 2ª parte
/
González Echevarría, Aurora (Universitat Autònoma de Barcelona. Departament d'Antropologia Social i Cultural) ;
García García, Carmen J. (Universitat Autònoma de Barcelona. Departament d'Antropologia Social i Cultural)
Este texto contiene dos partes. En la primera se discuten algunos desarrollos recientes de la Antropología Social y Cultural, que tienen en cuenta modelos evolutivos sobre parentalidad, es el correlato del artículo sobre aproximaciones biológicas a la parentalidad humana contenido en este volumen. [...]
This text is structured in two parts. The first one is a discussion of recent developments in social and cultural anthropology that take into account evolutionary models of parenthood. It is the correlate of the article on biological approaches to human parenthood contained in this volume. [...]
2016
Quaderns-e, Vol. 21 Núm. 2 (2016) , p. 153-172
|
|
|
9.
|
|
8 p, 509.4 KB |
GEIS-21 : A multicentric phase II study of intensive chemotherapy including gemcitabine and docetaxel for the treatment of Ewing sarcoma of children and adults: A report from the Spanish sarcoma group (GEIS)
/
Mora, J. (Hospital Sant Joan de Déu (Barcelona, Catalunya)) ;
Castañeda, A. (Hospital Sant Joan de Déu (Barcelona, Catalunya)) ;
Perez-Jaume, S. (Hospital Sant Joan de Déu (Barcelona, Catalunya)) ;
López Pousa, Antonio (Institut d'Investigació Biomèdica Sant Pau) ;
Maradiegue, E. (Hospital Sant Joan de Déu (Barcelona, Catalunya)) ;
Valverde, C. (Hospital Universitari Vall d'Hebron) ;
Martin-Broto, J. (Universidad de Sevilla) ;
Garcia Del Muro, X. (Hospital Universitari de Bellvitge) ;
Cruz, O. (Hospital Sant Joan de Déu (Barcelona, Catalunya)) ;
Cruz, J. (Hospital Universitario de Canarias (La Laguna)) ;
Martinez-Trufero, J. (Hospital Universitario Miguel Servet (Saragossa)) ;
Maurel, J. (Hospital Clínic i Provincial de Barcelona) ;
Vaz, M.A. (Hospital Ramón y Cajal) ;
De Alava, E. (Universidad de Sevilla) ;
De Torres, C. (Hospital Sant Joan de Déu (Barcelona, Catalunya)) ;
Universitat Autònoma de Barcelona
First Spanish trial of Ewing sarcoma (ES) including adults and children with the aim to test the efficacy of Gemcitabine and Docetaxel (G/D) in newly diagnosed high-risk (HR) patients. This was a prospective, multicentric, non-randomised, open study for patients 1/240 years with newly diagnosed ES. [...]
2017 - 10.1038/bjc.2017.252
British Journal of Cancer, Vol. 117 Núm. 6 (may 2017) , p. 767-774
|
|
|
10.
|
|
11 p, 1.2 MB |
Clinical outcome and biomarker assessments of a multi-centre phase II trial assessing niraparib with or without dostarlimab in recurrent endometrial carcinoma
/
Madariaga, Ainhoa (Universitat Autònoma de Barcelona) ;
Garg, Swati (University Health Network, Toronto, Canada) ;
Tchrakian, Nairi (University Health Network, Toronto, Canada) ;
Dhani, Neesha C. (University of Toronto, Canada) ;
Jimenez, Waldo (Juravinski Cancer Centre, Hamilton, Canada) ;
Welch, Stephen (London Health Sciences Center, London, Canada) ;
MacKay, Helen (Odette Cancer Centre. Sunnybrook Health Sciences Centre, Toronto, Canada) ;
Ethier, Josee-Lyne (Kingston Health Sciences Cancer Centre, Kingston, Canada) ;
Gilbert, Lucy (Royal Victoria Hospital, Montréal, Canada) ;
Li, Xuan (University Health Network, Toronto, Canada) ;
Rodriguez, Angela (University Health Network, Toronto, Canada) ;
Chan, Lucy (University Health Network, Toronto, Canada) ;
Bowering, Valerie (University Health Network, Toronto, Canada) ;
Clarke, Blaise (University Health Network, Toronto, Canada) ;
Zhang, Tong (University of Toronto, Canada) ;
King, Ian (University of Toronto, Canada) ;
Downs, Gregory (University of Toronto, Canada) ;
Stockley, Tracy (University of Toronto, Canada) ;
Wang, Lisa (University of Toronto, Toronto, Canada) ;
Udagani, Smitha (University Health Network, Toronto, Canada) ;
Oza, Amit M. (University of Toronto, Canada) ;
Lheureux, Stephanie (University of Toronto, Canada)
This multi-centre, non-randomized, open-label, phase II trial (NCT03016338), assessed niraparib monotherapy (cohort 1, C1), or niraparib and dostarlimab (cohort 2, C2) in patients with recurrent serous or endometrioid endometrial carcinoma. [...]
2023 - 10.1038/s41467-023-37084-w
Nature communications, Vol. 14 (2023) , art. 1452
|
|
guest ::
email alert
or subscribe to the 
RSS feed.
